Evotec, Novo Nordisk Drug Discovery Accelerator Selects First Three Projects for Cardiometabolic Conditions

MT Newswires Live2024-12-11

Evotec (EVO) said Wednesday that LAB eN2, its translational drug discovery accelerator with Novo Nordisk (NVO), has chosen its first three projects with Boston University, Harvard University, and the Joslin Diabetes Center.

Financial terms of the projects weren't disclosed.

The projects will focus on research for different cardiometabolic conditions and will be initially financed with a Discovery Award to attain select pre-clinical value-inflection points, the company added.

Evotec said LAB eN2 also intends to include Boston Children's Hospital, Boston University, Johns Hopkins University, and the Icahn School of Medicine at Mount Sinai.

The companies partnered in September last year to roll out LAB eN2, which focuses on therapeutics for cardiometabolic diseases and rare blood and endocrine disorders.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2490538618?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-11 19:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2490538618","market":"sg","top_or_hot":-1,"title":"Evotec, Novo Nordisk Drug Discovery Accelerator Selects First Three Projects for Cardiometabolic Conditions","media":"MT Newswires Live","content":"<html><body><p> Evotec (EVO) said Wednesday that LAB eN2, its translational drug discovery accelerator with Novo Nordisk (NVO), has chosen its first three projects with Boston University, Harvard University, and the Joslin Diabetes Center.</p><p>Financial terms of the projects weren't disclosed.</p><p>The projects will focus on research for different cardiometabolic conditions and will be initially financed with a Discovery Award to attain select pre-clinical value-inflection points, the company added.</p><p>Evotec said LAB eN2 also intends to include Boston Children's Hospital, Boston University, Johns Hopkins University, and the Icahn School of Medicine at Mount Sinai.</p><p>The companies partnered in September last year to roll out LAB eN2, which focuses on therapeutics for cardiometabolic diseases and rare blood and endocrine disorders.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Evotec, Novo Nordisk Drug Discovery Accelerator Selects First Three Projects for Cardiometabolic Conditions</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEvotec, Novo Nordisk Drug Discovery Accelerator Selects First Three Projects for Cardiometabolic Conditions\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-11 19:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Evotec (EVO) said Wednesday that LAB eN2, its translational drug discovery accelerator with Novo Nordisk (NVO), has chosen its first three projects with Boston University, Harvard University, and the ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EVO.AU","symbol_name":"EMBARK EARLY EDUCATION LTD","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2490538618","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2490538618","pubTimestamp":1733918078,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Evotec  said Wednesday that LAB eN2, its translational drug discovery accelerator with Novo Nordisk , has chosen its first three projects with Boston University, Harvard University, and the Joslin Diabetes Center.Financial terms of the projects weren't disclosed.The projects will focus on research for different cardiometabolic conditions and will be initially financed with a Discovery Award to attain select pre-clinical value-inflection points, the company added.Evotec said LAB eN2 also intends to include Boston Children's Hospital, Boston University, Johns Hopkins University, and the Icahn School of Medicine at Mount Sinai.The companies partnered in September last year to roll out LAB eN2, which focuses on therapeutics for cardiometabolic diseases and rare blood and endocrine disorders.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"EVO.AU":"EMBARK EARLY EDUCATION LTD","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","NVO.AU":"NOVO RESOURCES CORP-CDI","NVO":"诺和诺德","BK7104":"黄金","BK4588":"碎股","EVO":"Evotec SE","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","BK4007":"制药","BK4599":"减肥药","BK4585":"ETF&股票定投概念","BK4121":"生命科学工具和服务","BK7132":"教育服务","BK4532":"文艺复兴科技持仓","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD"},"translate_title":"Evotec与诺和诺德药物发现加速器选择前三个针对心脏代谢疾病的项目","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVO.AU":1,"NVO":1,"EVO.AU":1,"EVO":0.9},"content_text":"Evotec (EVO) said Wednesday that LAB eN2, its translational drug discovery accelerator with Novo Nordisk (NVO), has chosen its first three projects with Boston University, Harvard University, and the Joslin Diabetes Center.Financial terms of the projects weren't disclosed.The projects will focus on research for different cardiometabolic conditions and will be initially financed with a Discovery Award to attain select pre-clinical value-inflection points, the company added.Evotec said LAB eN2 also intends to include Boston Children's Hospital, Boston University, Johns Hopkins University, and the Icahn School of Medicine at Mount Sinai.The companies partnered in September last year to roll out LAB eN2, which focuses on therapeutics for cardiometabolic diseases and rare blood and endocrine disorders.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.0","shortVersion":"4.30.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2490538618"}